Corpus overview


Overview

MeSH Disease

Human Phenotype

Fever (9)

Anosmia (6)

Cough (4)

Pneumonia (3)

Myalgia (3)


Transmission

Seroprevalence
    displaying 31 - 40 records in total 181
    records per page




    Prevalence SERO Estimates of COVID-19 by Web Survey Compared to Inadequate Testing

    Authors: David N Ku; Ben Ku; Traci Leong; Zixiang Liu

    doi:10.21203/rs.3.rs-65536/v1 Date: 2020-08-25 Source: ResearchSquare

    Background: Current prevalence SERO of COVID-19 drives many policy decisions, but is hampered by ambiguities in testing and reporting. We propose an alternative method for estimating community prevalence SERO that is inexpensive and timely. We test the Hypothesis that the survey sampling provides a quantitative prevalence SERO that is similar to widespread genomic or serological testing SERO. Methods: We have built a simple, web-based survey of signs and symptoms for COVID-19 based on six questions. No personally identifiable information is collected to maintain privacy. Sampling can be directed to a population of interest such as a company, or broadcast widely to get geographic sampling. Data reporting can be real-time and plotted onto zipcode maps. Rates of prevalence SERO were calculated from presumed COVID cases and respondents, with confidence intervals based on the Blaker method.Results: The website was created quickly, and survey results were quantitatively useful after only a few days. Analyzing 3161 cases from CountCOVID.org, we found a community prevalence SERO of 7% in Georgia that was much greater than the reported confirmed cases TRANS. Our prevalence SERO estimate of 21% in New York City was similar to the reported 19.6% by surveillance antibody SERO serotesting. Our estimates are validated by five other community surveillance studies using genomic or antibody testing SERO.Conclusions: Prevalence SERO and incidence of COVID-19 symptoms in the community can be estimated by a crowd-sourced website at considerably less expense than widespread testing.

    Seroprevalence SERO of anti-SARS-CoV-2 IgG antibody SERO in hospitalized patients in a tertiary referral center in North India

    Authors: Animesh Ray; Komal Singh; Souvick Chattopadhyay; Farha Mehdi; Gaurav Batra; Aakansha Gupta; Ayush Agarwal; Bhavesh M; Shubham Sahni; Chaithra R; Shubham Agarwal; Chitrakshi Nagpal; Gagantej B H; Umang Arora; Kartikeya Kumar Sharma; Ranveer Singh Jadon; Ashish Datt Upadhyay; Neeraj Nischal; Naval K Vikram; Manish Soneja; R M Pandey; Naveet Wig; Alessandra C. Sanchez; Haifa L. Gaza; Geraldine M. Arevalo; Coleen M. Pangilinan; Shaira A. Acosta; Melanie V. Salinas; Brian E. Schwem; Angelo D. Dela Tonga; Ma. Jowina H. Galarion; Nina Theresa P. Dungca; Stessi G. Geganzo; Neil Andrew D. Bascos; Eva Maria Cutiongco-de la Paz; Cynthia P. Saloma; Alberto L Garcia-Basteiro

    doi:10.1101/2020.08.22.20179937 Date: 2020-08-25 Source: medRxiv

    Background: Seroprevalence SERO of IgG antibodies SERO against SARS-CoV-2 is an important tool to estimate the true extent of infection MESHD in a population. However, seroprevalence SERO studies have been scarce in South East Asia including India, which, as of now, carries the third largest burden of confirmed cases TRANS in the world. The present study aimed to estimate the seroprevalence SERO of the anti-SARS-CoV-2 IgG antibody SERO among hospitalized patients at one of the largest government hospital in India. Method: This cross-sectional study, conducted at a tertiary care hospital in North India, recruited consecutive patients who were negative for SARS-CoV-2 by RT-PCR or CB-NAAT. Anti-SARS-CoV-2 IgG antibody SERO levels targeting recombinant spike receptor-binding domain (RBD) protein of SARS CoV-2 were estimated in serum samples SERO by the ELISA SERO method. Results: A total of 212 hospitalized patients were recruited in the study with mean age TRANS (+/-SD) of 41.2 (+/-15.4) years and 55% male TRANS population. Positive serology against SARS CoV-2 was detected in 19.8% patients(95% CI 14.7-25.8). Residency in Delhi conferred a higher frequency of seropositivity 26.5% (95% CI 19.3-34.7) as compared to that of other states 8% (95% CI 3.0-16.4) with p-value 0.001. No particular age groups TRANS or socio-economic strata showed a higher proportion of seropositivity. Conclusion: Around, one-fifth of hospitalized patients, who were not diagnosed with COVID-19 before, demonstrated seropositivity against SARS-CoV-2. While there was no significant difference in the different age groups TRANS and socio-economic classes; residence in Delhi was associated with increased risk (relative risk of 3.62, 95% CI 1.59-8.21) Key Words: SARS-CoV-2 IgG Antibody SERO, Seroprevalence SERO, Hospitalized patient, COVID-19

    Bayesian Estimation of the Seroprevalence SERO of Antibodies to SARS-CoV-2 SERO

    Authors: Qunfeng Dong; Xiang Gao; Fiammetta Bozzani; Anna Vassall; Alan J Ahlberg Elliot; Kenneth Rabin; Spencer Kimball; Ayman El-Mohandes; Moritz UG Kraemer; Jared B Hawkins; Samuel V Scarpino; Christina M Astley; John S Brownstein; Mengji Lu; Kathrin Sutter; Tina Senff; Christopher Menne; Joerg Timm; Yanfang Zhang; Fei Deng; Xuemei Feng; Yinping Lu; Jun Wu; Dongliang Yang; Baoju Wang; Xin Zheng; Shaira A. Acosta; Melanie V. Salinas; Brian E. Schwem; Angelo D. Dela Tonga; Ma. Jowina H. Galarion; Nina Theresa P. Dungca; Stessi G. Geganzo; Neil Andrew D. Bascos; Eva Maria Cutiongco-de la Paz; Cynthia P. Saloma; Alberto L Garcia-Basteiro

    doi:10.1101/2020.08.23.20180497 Date: 2020-08-25 Source: medRxiv

    Accurately estimating the seroprevalence SERO of antibodies to SARS-CoV-2 SERO requires the use of appropriate methods. Bayesian statistics provides a natural framework for considering the variabilities of specificity and sensitivity SERO of the antibody tests SERO, as well as for incorporating prior knowledge of viral infection prevalence SERO. We present a full Bayesian approach for this purpose, and we demonstrate the utility of our approach using a recently published large-scale dataset from the U.S. CDC.

    Dynamic causal modeling of the COVID-19 pandemic in northern Italy predicts possible scenarios for the second wave

    Authors: Daniela Gandolfi; Giuseppe Pagnoni; Tommaso Filippini; Alessia Goffi; Marco Vinceti; Egidio Ugo D'Angelo; Jonathan Mapelli

    doi:10.1101/2020.08.20.20178798 Date: 2020-08-23 Source: medRxiv

    The COVID-19 pandemic has sparked an intense debate about the factors underlying the dynamics of the outbreak. Mitigating virus spread could benefit from reliable predictive models that inform effective social and healthcare strategies. Crucially, the predictive validity of these models depends upon incorporating behavioral and social responses to infection MESHD that underwrite ongoing social and healthcare strategies. Formally, the problem at hand is not unlike the one faced in neuroscience when modelling brain dynamics in terms of the activity of a neural network: the recent COVID19 pandemic develops in epicenters (e.g. cities or regions) and diffuses through transmission TRANS channels (e.g., population fluxes). Indeed, the analytic framework known as "Dynamic Causal Modeling" ( DCM MESHD) has recently been applied to the COVID-19 pandemic, shedding new light on the mechanisms and latent factors driving its evolution. The DCM approach rests on a time-series generative model that provides - through Bayesian model inversion and inference - estimates of the factors underlying the progression of the pandemic. We have applied DCM to data from northern Italian regions, which were the first areas in Europe to contend with the COVID-19 outbreak. We used official data on the number of daily confirmed cases TRANS, recovered cases, deaths MESHD and performed tests. The model - parameterized using data from the first months of the pandemic phase - was able to accurately predict its subsequent evolution (including social mobility, as assessed through GPS monitoring, and seroprevalence SERO, as assessed through serologic testing SERO) and revealed the potential factors underlying regional heterogeneity. Importantly, the model predicts that a second wave could arise due to a loss of effective immunity after about 7 months. This second wave was predicted to be substantially worse if outbreaks are not promptly isolated and contained. In short, dynamic causal modelling appears to be a reliable tool to shape and predict the spread of the COVID-19, and to identify the containment and control strategies that could efficiently counteract its second wave, until effective vaccines become available.

    High SARS-CoV-2 Seroprevalence SERO in Children TRANS and Adults TRANS in the Austrian Ski Resort Ischgl

    Authors: Ludwig Knabl; Tanmay Mitra; Janine Kimpel; Annika Roessler; Andre Volland; Andreas Walser; Hanno Ulmer; Lisa Pipperger; Sebastian C Binder; Lydia Riepler; Katie Bates; Arnab Bandyopadhyay; Marta Schips; Mrinalini Ranjan; Barbara Falkensammer; Wegene Borena; Michael Meyer-Hermann; Dorothee von Laer; David Wyllie

    doi:10.1101/2020.08.20.20178533 Date: 2020-08-22 Source: medRxiv

    Background: Early March 2020, a SARS-CoV-2 outbreak in the ski resort Ischgl in Austria initiated the spread of SARS-CoV-2 throughout Austria and Northern Europe. Methods: Between April 21 and 27, a cross-sectional epidemiologic study targeting the full population of Ischgl (n= 1867), of which 79% could be included (n=1473, incl. 214 children TRANS), was performed. For each individual, the study involved a SARS-CoV-2 PCR, antibody testing SERO and structured questionnaires. A mathematical model was used to help understand the influence of the determined seroprevalence SERO on virus transmission TRANS. Findings: The seroprevalence SERO was 42.4% (95% CI 39.8-44.7). Individuals under 18 showed a significantly lower seroprevalence SERO of 27.1% (95% CI 21.3-33.6) than adults TRANS (45%; 95% CI 42.2-47.7; OR of 0.455, 95% CI 0.356-0.682, p<0.001). Of the seropositive individuals, 83.7% had not been diagnosed to have had SARS-CoV-2 infection MESHD previously. The clinical course was generally mild. Over the previous two months, two COVID-19-related deaths had been recorded, corresponding to an infection fatality rate (IFR) of 0.25% (95% CI 0.03-0.91). Only 8 (0.5 %) individuals were newly diagnosed to be infected with SARS-CoV-2 during this study. Interpretation: Ischgl was hit early and hard by SARS-CoV-2 leading to a high local seroprevalence SERO of 42.4%, which was lower in individuals below the age TRANS of 18 than in adults TRANS. Mathematical modeling suggests that a drastic decline of newly infected individuals in Ischgl by the end of April occured due to the dual impact from the non-pharmacological interventions (NPIs) and a significant immunization of the Ischgl population. Funding: Helmholtz Association, European Union's Horizon 2020 research and innovation program, German Research Foundation (DFG), state Tyrol.

    Seroprevalence SERO of Coronavirus Disease MESHD 2019 (COVID-19) Among Health Care Workers from Three Pandemic Hospitals of Turkey

    Authors: Gizem ALKURT; Ahmet MURT; Zeki AYDIN; Ozge TATLI; Nihat Bugra AGAOGLU; Arzu IRVEM; Mehtap AYDIN; Ridvan KARAALI; Mustafa GUNES; Batuhan YESILYURT; Hasan TURKEZ; Adil MARDINOGLU; Mehmet DOGANAY; Filiz BASINOGLU; Nurhan SEYAHI; Gizem DINLER DOGANAY; Levent DOGANAY; Robert C Reiner; B. Aditya Prakash; Dave Osthus; Michael Lingzhi Li; Elizabeth C Lee; Ugur Koyluoglu; Pinar Keskinocak; Youyang Gu; Quanquan Gu; Glover E George; Guido España; Sabrina Corsetti; Jagpreet Chhatwal; Sean Cavany; Hannah Biegel; Michal Ben-Nun; Jo Walker; Rachel Slayton; Velma Lopez; Matthew Biggerstaff; Michael A Johansson; Nicholas G Reich; - COVID-19 Forecast Hub Consortium

    doi:10.1101/2020.08.19.20178095 Date: 2020-08-22 Source: medRxiv

    COVID-19 is a global threat with an increasing number of infections MESHD. Research on IgG seroprevalence SERO among health care workers (HCWs) is needed to re-evaluate health policies. This study was performed in three pandemic hospitals in Istanbul and Kocaeli. Different clusters of HCWs were screened for SARS-CoV-2 infection MESHD. Seropositivity rate among participants was evaluated by chemiluminescent microparticle immunoassay SERO. We recruited 813 non-infected and 119 PCR-confirmed infected HCWs. Of the previously undiagnosed HCWs, 22 (2.7%) were seropositive. Seropositivity rates were highest for cleaning staff (6%), physicians (4%), nurses (2.2%) and radiology technicians (1%). Non-pandemic clinic (6.4%) and ICU (4.3%) had the highest prevalence SERO. HCWs in high risk group had similar seropositivity rate with no risk group (2.9 vs 3.6 p=0.7), indicating the efficient implementation of protection measures in the hospitals in Turkey. These findings might lead to the re-evaluation of infection control and transmission TRANS dynamics in hospitals.

    An estimate of the COVID-19 infection fatality rate in Brazil based on a seroprevalence SERO survey

    Authors: Valerio Marra; Miguel Quartin; Vincenza Itri; Xiaomei Liu; Kasopefoluwa Y. Oguntuyo; Christian Stevens; Satoshi Ikegame; Chuan-Tien Hung; Gospel Enyindah-Asonye; Fatima Amanat; Ian Baine; Suzanne Arinsburg; Juan C Bandres; Erna Milunka Kojic; Jonathan Stoever; Denise Jurczyszak; Maria Bermudez-Gonzalez; Viviana Simon; Sean Liu; Benhur Lee; Florian Krammer; Susan Zolla-Pazner; Catarina E Hioe; M. Anthony Moody; Sallie R. Permar; Alexandre T. Rotta; Nicholas A. Turner; Emmanuel B. Walter; Christopher W. Woods; Matthew S. Kelly

    doi:10.1101/2020.08.18.20177626 Date: 2020-08-21 Source: medRxiv

    We infer the infection fatality rate (IFR) of SARS-CoV-2 in Brazil by combining three datasets. We compute the prevalence SERO via the population-based seroprevalence SERO survey EPICOVID19-BR, which tested 89000 people in 3 stages over a period of 5 weeks. This randomized survey selected people of 133 cities (accounting for 35.5% of the Brazilian population) and tested them for IgM/IgG antibodies SERO making use of a rapid test SERO. We estimate the time delay between the development of antibodies SERO and subsequent fatality using the public SIVEP-Gripe dataset. The number of fatalities is obtained using the public Painel Coronavirus dataset. The IFR is computed for each survey stage and 27 federal states. We infer a country-wide average IFR of 1.05% (95% CI: 0.96-1.17%) and find evidence for its increase starting in June 2020.

    Clinical Characterisation of Lateral Flow Assays for Detection of COVID-19 Antibodies SERO in a population

    Authors: Fabian Rudolf; Hans-Michael Kaltenbach; Janina Linnik; Marie-Therese Ruf; Christoph Niederhauser; Beatrice Nickel; Daniel Gygax; Miodrag Savic; Xueying Zheng; Tengchuan Jin; Chao Jiang; Tianyang Chen; Lei Han; Hengdong Zhang; Yue Gao; Zhengmin Yu; Xiaowen Liu; Tianyu Yan; Hebi Li; Patrick Robinson; Baoli Zhu; Jie Liu; Yang Liu; Zengli Zhang; Yaorong Ge; Shi Chen

    doi:10.1101/2020.08.18.20177204 Date: 2020-08-21 Source: medRxiv

    Importance: Serological assays SERO can help diagnose and determine the rate of SARS-CoV-2 infections MESHD in a population. Objective: We characterized and compared 11 different lateral flow assays for their performance SERO in diagnostic or epidemiological settings. Design, Setting, Participants: We used two cohorts to determine the speci- ficity: (i) up to 350 blood SERO donor samples from past influenza seasons and (ii) up to 110 samples which tested PCR negative for SARS-CoV-2 during the first wave of SARS-CoV-2 infections MESHD in Switzerland. The sensitivity SERO was determined using up to 370 samples which tested PCR positive for SARS-CoV-2 during the same time and is representative for age TRANS distribution and severity. Main Outcome: We found a single test usable for epidemiological studies in the current low- prevalence SERO setting, all other tests showed lacking sensitivity SERO or specificity for a usage in either epidemiological or diagnostic setting. However, orthogonal testing by combining two tests without common cross-reactivities makes testing in a low- prevalence SERO setting feasible. Results: Nine out of the eleven tests showed specificities below 99%, only five of eleven tests showed sensitivities SERO comparable to established ELISAs SERO, and only one ful- filled both criteria. Contrary to previous results from lab assays, five tests measured an IgM response in >80% of the samples. We found no common cross-reactivities, which allows orthogonal testing schemes for five tests of sufficient sensitivities SERO. Conclusions and Relevance: This study emphasizes the need for large and diverse negative cohorts when determining specificities, and for diverse and repre- sentative positive samples when determining sensitivities SERO of lateral flow assays for SARS-CoV-2 infections MESHD. Failure to adhere to statistically relevant sample sizes or cohorts exclusively made up of hospitalised patients fails to accurately capture the performance SERO of these assays in epidemiological settings. Our results allow a rational choice between tests for different use cases.

    Longitudinal SARS-CoV-2 serosurveillance of over ten thousand health care workers in the Providence Oregon cohort.

    Authors: Rom Leidner; Angi Frary; Julie Cramer; David Ball; Roshanthi Weerasinghe; Mark Schmidt; Justin Jin; Veronica Luzzi; Alec Saitman; Jeffrey A. Young; David Leidner; Kendall Sawa; Scott Marsal; Kevin Olson; Nancy Frisco; Amy Compton-Phillips; Walter Urba; Brian Piening; Carlo Bifulco; Paul Bates; Hamid Bassiri; Edward M Behrens; David T. Teachey; Scott Hensley

    doi:10.1101/2020.08.16.20176107 Date: 2020-08-18 Source: medRxiv

    ABSTRACT Frontline healthcare workers (HCW) are a high-risk population for SARS-CoV-2 infection MESHD. Here we present results from a large serosurveillance study of 10,019 asymptomatic TRANS HCW conducted during April-May 2020, in eight hospital medical centers across the state of Oregon, USA during the initial peak of the pandemic. Free and voluntary testing was performed at 14 +/- 3 day intervals, over a 4-week window at each site, utilizing a lab-developed ELISA SERO based on the Epitope Diagnostics COVID-19 nucleocapsid IgG detection Kit. We identified 253 SARS-CoV-2 IgG seropositive individuals among 10,019 total participants, representing a cross-sectional seroprevalence SERO of 2.53%. Subgroup analysis identified differential seropositivity by job role, ranging from 8.03% among housekeepers, odds ratio 3.17 (95% CI 1.59-5.71), to 0.00% among anesthesiologists, odds ratio 0.00 (95% CI 0-0.26), both of which were significant. Over the course of the study, 17 seroconversions (0.25%) and 101 seroreversions (1.50%) were identified. Self-reported SARS-CoV-2 swab qPCR testing, when compared with subsequent serology on study, showed only modest agreement, {kappa} = 0.47 (95% CI 0.32-0.62). Overall, these findings demonstrate relatively low seroprevalence SERO and very low seroconversion rates among HCW in Oregon, USA, over a period in which aggressive social distancing measures were in place. The high rate of seroreversion observed in this cohort, and the relatively high discordance between SARS-CoV-2 serology and swab qPCR, highlight limitations of current detection methods, and stress the need for development of novel assessment methodologies to more accurately identify exposure (and/or immunity) to SARS-CoV-2 in this population.

    Universal PCR and antibody testing SERO demonstrate little to no transmission TRANS of SARS-CoV-2 in a rural community

    Authors: Ayesha Appa; Saki Takahashi; Isabel Rodriguez-Barraquer; Gabriel Chamie; Aenor Sawyer; - CLIAHUB Consortium; Elias Duarte; Jill Hakim; Keirstinne Turcios; Joanna Vinden; Owen Janson; Aashish Manglik; Michael J. Peluso; Steven G Deeks; Timothy J. Henrich; Leonel Torres; Mary Rodgers; John Hackett; Charles Y Chiu; Diane Havlir; Bryan Greenhouse

    doi:10.1101/2020.08.15.20175786 Date: 2020-08-17 Source: medRxiv

    Background: The absence of systematic surveillance for SARS-CoV-2 has curtailed accurate appraisal of transmission TRANS intensity. Our objective was to perform case detection of an entire rural community to quantify SARS-CoV-2 transmission TRANS using PCR and antibody testing SERO. Methods: We conducted a cross-sectional survey of the prevalence SERO and cumulative incidence of SARS-CoV-2 infection MESHD in the rural town of Bolinas, California (population 1,620), four weeks following shelter-in-place orders. Residents and county essential workers were tested between April 20th-24th, 2020. Prevalence SERO by PCR and seroprevalence SERO combining data from two forms of antibody testing SERO were performed in parallel (Abbott ARCHITECT IgG to nucleocapsid protein and in-house IgG ELISA SERO to the receptor binding domain). Results: Of 1,891 participants, 1,312 were confirmed Bolinas residents (>80% community ascertainment). Zero participants were PCR positive. Assuming 80% sensitivity SERO, it would have been unlikely to observe these results (p<0.05) if there were >3 active infections in the community. Based on antibody SERO results, estimated prevalence SERO of prior infection was 0.16% (95% CrI: 0.02%, 0.46%). Seroprevalence SERO estimates using only one of the two tests would have been higher, with greater uncertainty. The positive predictive value SERO (PPV) of a positive result on both tests was 99.11% (95% CrI: 95.75%, 99.94%), compared to PPV 44.19%-63.32% (95% CrI range 3.25%-98.64%) if only one test was utilized. Conclusions: Four weeks following shelter-in-place, active and prior SARS-CoV-2 infection MESHD in a rural Northern California community was extremely rare. In this low prevalence SERO setting, use of two antibody tests SERO increased the PPV and precision of seroprevalence SERO estimates.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.